These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34599981)

  • 1. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.
    Jiang Y; Zhuo X; Wu Y; Fu X; Mao C
    Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119144. PubMed ID: 34599981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
    Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
    Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.
    Zhou J; Wang X; Li Z; Wang F; Cao L; Chen X; Huang D; Jiang R
    Cell Death Dis; 2024 Sep; 15(9):644. PubMed ID: 39227379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
    Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
    BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
    Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer.
    Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
    Thorac Cancer; 2021 Jun; 12(11):1708-1715. PubMed ID: 33943009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
    Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
    Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
    Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK; Wei W; Sun SY
    Mol Cancer Res; 2021 Oct; 19(10):1622-1634. PubMed ID: 34183449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
    Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
    Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip.
    Tan J; Zhu L; Shi J; Zhang J; Kuang J; Guo Q; Zhu X; Chen Y; Zhou C; Gao X
    Eur J Pharm Sci; 2024 Aug; 199():106805. PubMed ID: 38763450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
    Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
    Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation.
    Jiang Y; Zhuo X; Fu X; Wu Y; Mao C
    Front Pharmacol; 2021; 12():625289. PubMed ID: 33967759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Onda N; Nakamichi S; Hirao M; Matsuda K; Matsumoto M; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Sci; 2024 Aug; 115(8):2718-2728. PubMed ID: 38941131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.
    Takahashi A; Seike M; Chiba M; Takahashi S; Nakamichi S; Matsumoto M; Takeuchi S; Minegishi Y; Noro R; Kunugi S; Kubota K; Gemma A
    Sci Rep; 2018 Oct; 8(1):14896. PubMed ID: 30291293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
    Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
    Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.